A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of different subcutaneous starting doses and
dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on
dialysis. The anticipated time on study treatment is 3-12 months and the target sample size
is <100 individuals.